Ocata Therapeutics (Formerly Known As Advanced Cell Technology)
33 Locke Drive
Marlborough
Massachusetts
01752
United States
Tel: 580-756-1212
Fax: 580-229-2333
Website: http://ir.ocata.com/
347 articles about Ocata Therapeutics (Formerly Known As Advanced Cell Technology)
-
Astellas Announces Results Of Tender Offer To Acquire All Outstanding Shares Of Ocata And Changes To Subsidiaries
2/10/2016
-
Astellas Extends Tender Offer To Acquire All Outstanding Shares Of Ocata
1/22/2016
-
Ocata Reports The Publication Of Data About The Generation Of Corneal Endothelial Cells From Human Pluripotent Stem Cells
12/28/2015
-
Ocata’s Hemangio-Derived Mesenchymal Cells Preserve Kidney Function And Extend Lifespan In Preclinical Model Of Lupus Nephritis
12/3/2015
-
Astellas Snaps Up Stem Cell Pioneer Ocata in $379 Million Deal
11/10/2015
-
Ocata Therapeutics To Host Conference Call And Webcast To Provide Corporate Update For The Third Quarter
11/9/2015
-
Ocata Therapeutics To Present At Ladenburg Thalmann 2015 Healthcare Conference
9/23/2015
-
Canine Patients Treated With Ocata Therapeutics’s Hemangio-Derived Mesenchymal Cells (HMC) Achieve Remission In A Model Of Crohn’s Disease
9/22/2015
-
First Patient Enrolled In Ocata Therapeutics’ Phase II Study For Dry AMD
9/8/2015
-
Dr. Robert Lanza, Chief Scientific Officer Of Ocata Therapeutics Awarded The Honor Of iPSC Industry Influencer
9/3/2015
-
Ocata Therapeutics Receives SBIR Grant From The NIH’s National Eye Institute To Develop Proprietary Photoreceptor Progenitor Cell Therapy For Retinitis Pigmentosa
9/1/2015
-
Ocata Therapeutics Appoints Dr. Brian Levy To Its Board Of Directors
8/31/2015
-
Ocata Therapeutics Receives SBIR Grant From NIH To Develop Proprietary Hemangio-Derived Mesenchymal Cell Therapy For Lupus Nephritis
8/24/2015
-
Ocata Therapeutics Secures $10 Million In Debt Financing
8/19/2015
-
Ocata Therapeutics Provides Corporate Update For The Second Quarter Of 2015
8/7/2015
-
Ocata Therapeutics To Host Conference Call And Webcast To Provide Corporate Update For The Second Quarter Of 2015
7/31/2015
-
Ocata Therapeutics Receives New U.S. Patent For Its RPE Therapy For Macular Degenerative Diseases
7/15/2015
-
Ocata Therapeutics Announces New Pre-Clinical Data To Be Reported At The International Congress On Systemic Lupus Erythematosus
7/14/2015
-
Ocata Therapeutics To Present At The Cantor Fitzgerald Inaugural Healthcare Conference
7/1/2015
-
Ocata Therapeutics To Present At The Cantor Fitzgerald Inaugural Healthcare Conference
7/1/2015